TrialJAMA oncology2018

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

Amir T Fathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.